Evidence map›Paper›PMID 40820797›Full record

ArticleHaematologica2026

Bortezomib-melphalan-prednisone <I>versus</i> lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.

Sara Bringhen, Lorenzo Cani, Nicola Giuliani, Silvia Mangiacavalli, Giulia Benevolo, Elisabetta Antonioli, Renato Zambello, Roberto Ria, Iolanda Donatella Vincelli, Sonia Ronconi and 20 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Sara BringhenSSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology, AOU Citta della Salute e della Scienza di Torino, University of Torino, Torino. sarabringhen@yahoo.com.
Lorenzo CaniDivision of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino.
Nicola GiulianiUniversity of Parma and AOU Parma, Parma.
Silvia MangiacavalliDivision of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia.
Giulia BenevoloSSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Department of Oncology, AOU Citta della Salute e della Scienza di Torino, University of Torino, Torino.
Elisabetta AntonioliHematology Unit, AOU Careggi, Florence.
Renato ZambelloDepartment of Medicine (DIMED), Hematology, Padua University, Padua.
Roberto RiaUniversity of Bari Aldo Moro Medical School, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Bari.
Iolanda Donatella VincelliDivisione di Ematologia, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria.
Sonia RonconiIRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola.
Sonia MoreAOU delle Marche, Universita Politecnica delle Marche, Ancona.
Antonietta Pia FalconeHematology, IRCCS "Casa Sollievo della Sofferenza" Hospital, San Giovanni Rotondo.
Alessandro AllegraDivision of Hematology, Department of Human Pathology in Adulthood and Childhood "Gaetano Barresi", University of Messina, Messina.
Mattia D'AgostinoDivision of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino.
Andrea EvangelistaUnit of Clinical Epidemiology, AOU Citta della Salute e della Scienza di Torino and CPO Piemonte, Torino.
Andrea CapraEuropean Myeloma Network (EMN).
Elisa SciorsciSC Farmacia Ospedaliera, AOU Citta della Salute e della Scienza di Torino, Torino.
Paola CurciHematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari.
Patrizia TosiUO Ematologia, Ospedale di Rimini, Rimini.
Anna Marina LiberatiA.O. Santa Maria di Terni - Universita degli Studi di Perugia, Terni-Perugia.
Anna Maria CafroSC Ematologia, GOM Niguarda, Milano.
Angelo BelottiDepartment of Hematology, ASST Spedali Civili di Brescia, Brescia.
Francesca PatriarcaHematologic Clinic and Transplant Center, University Hospital of Central Friuli, DMED, University of Udine, Udine.
Donato ManninaOncology-Hematology Department, Papardo Hospital, Messina.
Katia MancusoIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Bologna, Italy; Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna.
Francesco CattelSC Farmacia Ospedaliera, AOU Citta della Salute e della Scienza di Torino, Torino.
Giovannino CicconeUnit of Clinical Epidemiology, AOU Citta della Salute e della Scienza di Torino and CPO Piemonte, Torino.
Benedetto BrunoDivision of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino.
Mario BoccadoroEuropean Myeloma Network (EMN), Italy; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino.
Alessandra LaroccaDivision of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40820797
PMCPMC12775744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.